Wild-type p53 antagonized NF-κB signaling inhibited the expression of cytokines and chemokines, and reduced the accumulation of ROS, thereby suppressing the inflammatory response in prostate cancer cells [17]. The gene discussed is TP53; the disease is prostate carcinoma.